Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
|08 Sep 2021||$0.4200||100.00%||Final||24 Sep 2021|
|22 Mar 2021||$0.2900||100.00%||Interim||12 Apr 2021|
|27 Aug 2019||$0.7000||100.00%||Final||12 Sep 2019|
|04 Mar 2019||$1.5000||100.00%||Interim||20 Mar 2019|
|26 Sep 2018||$1.5500||100.00%||Final||12 Oct 2018|
|07 Mar 2018||$1.5000||100.00%||Interim||22 Mar 2018|
|11 Sep 2017||$1.4000||100.00%||Final||26 Sep 2017|
|07 Mar 2017||$1.3000||100.00%||Interim||22 Mar 2017|
|06 Sep 2016||$2.1000||100.00%||Final||21 Sep 2016|
|09 Mar 2016||$2.0000||100.00%||Interim||24 Mar 2016|
|04 Sep 2015||$1.3500||100.00%||22 Sep 2015|
|23 Mar 2015||$0.6800||100.00%||13 Apr 2015|
|10 Sep 2014||$0.8300||100.00%||Final||03 Oct 2014|
|05 Mar 2014||$0.4400||100.00%||Interim||02 Apr 2014|
|24 Sep 2013||$0.8300||100.00%||Final||18 Oct 2013|
|07 Mar 2013||$0.4400||100.00%||Interim||04 Apr 2013|
|25 Sep 2012||$0.8300||100.00%||Final||16 Oct 2012|
|04 Mar 2010||$0.4200||100.00%||Interim||25 Mar 2010|
|04 Sep 2009||$0.5700||100.00%||Final||24 Sep 2009|
|27 Feb 2009||$0.3900||100.00%||Interim||19 Mar 2009|
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Blackmores Limited (BKL) is Australia’s leading natural health company, providing a range of vitamin, minerals, herbal and nutritional supplements to communities around the world. The company was founded by the vision and passion of Maurice Blackmore in 1931 and went on to publicly list on the ASX in 1985.
Since then, Blackmores has made a series of acquisitions along its journey and has expanded into key Asian markets. In 2015, Blackmores shares treated investors to some particularly enormous gains, while it also became the first company listed on the ASX to hit $200 per share.
|22 Oct 2021||$100.73||$-0.27||-0.27%||33,037||$99.81||$101.14||$98.61|
|21 Oct 2021||$101.00||$-1.22||-1.19%||33,974||$102.38||$102.45||$99.74|
|20 Oct 2021||$102.22||$4.08||4.16%||137,127||$98.85||$102.92||$98.06|
|19 Oct 2021||$98.14||$-1.02||-1.03%||38,410||$97.12||$99.44||$97.12|
|18 Oct 2021||$99.16||$-0.29||-0.29%||32,469||$99.80||$99.99||$98.17|
|15 Oct 2021||$99.45||$1.85||1.90%||47,440||$98.49||$99.78||$97.71|
|14 Oct 2021||$97.60||$1.06||1.10%||70,468||$98.01||$98.50||$96.78|
|13 Oct 2021||$96.54||$0.86||0.90%||22,871||$95.00||$96.91||$94.82|
|12 Oct 2021||$95.68||$-0.99||-1.02%||43,375||$96.60||$98.50||$94.66|
|11 Oct 2021||$96.67||$1.46||1.53%||79,578||$95.66||$98.50||$95.00|
|08 Oct 2021||$95.21||$0.44||0.46%||26,944||$95.30||$96.00||$94.50|
|07 Oct 2021||$94.77||$0.69||0.73%||28,035||$94.90||$95.62||$93.40|
|06 Oct 2021||$94.08||$-0.52||-0.55%||37,138||$93.74||$95.04||$92.74|
|05 Oct 2021||$94.60||$1.01||1.08%||41,824||$92.50||$95.80||$92.50|
|04 Oct 2021||$93.59||$0.52||0.56%||23,835||$92.02||$95.04||$92.02|
|01 Oct 2021||$93.07||$-2.01||-2.11%||34,853||$92.50||$93.62||$91.05|
|30 Sep 2021||$95.08||$2.42||2.61%||28,578||$92.15||$95.08||$91.04|
|29 Sep 2021||$92.66||$-1.19||-1.27%||41,312||$90.30||$93.31||$89.30|
|28 Sep 2021||$93.85||$-0.88||-0.93%||79,461||$94.50||$95.54||$92.70|
|27 Sep 2021||$94.73||$1.73||1.86%||47,209||$92.98||$95.63||$90.90|
|24 Sep 2021||$93.00||$2.16||2.38%||44,104||$91.00||$94.82||$89.68|
|23 Sep 2021||$90.84||$1.61||1.80%||41,245||$89.95||$91.65||$89.30|
|22 Sep 2021||$89.23||$1.01||1.14%||43,132||$88.00||$89.99||$88.00|
|10 Jun 2021||Anne Templeman-Jones||Buy||652||$44,922|| |
On-market trade. Avg Price.
|10 May 2021||Wendy Stops||Buy||2||$170,504|| |
On-market trade. Avg price
|14 Dec 2020||Alastair Symington||Issued||38||$3,165,030|| |
Issue of securities. 73,986 - Right
|Mr Stephen Patrick Roche||Non-Executive Director||Sep 2021|| |
Mr Roche has ASX listed experience, as both a director and as a CEO. He has experience in strategy, business development and supply chains across the pharmacy, healthcare, retail and consumer markets. Stephen has over 20 years' experience in pharmacy, manufacturing operations and supply chains, developed in roles which include his eleven-year tenure as Managing Director and CEO of Australian Pharmaceutical Industries Limited (API). Stephen is currently Managing Director of Bridgestone Australia & New Zealand. Prior to his leadership of API, Stephen held senior executive roles at Mayne and Faulding extending across health and primary care services, distribution and business development. Stephen currently serves as a Non-Executive Director of Myer Family Investments Pty Ltd, Baby Bunting Limited and Adelaide Football Club. He was previously Vice Chairman of Bridgestone China & Asia Pacific, the founding Chairman of the Priceline Sisterhood Foundation and a Non-Executive Director of Epworth Healthcare and Gold Cross Products and Services.
|Ms Anne Louise Templeman-Jones||Non-Executive ChairmanNon-Executive Director||Oct 2020|| |
Ms Templeman-Jones brings a wealth of corporate experience and is currently serving as a Non-Executive Director of Commonwealth Bank of Australia, GUD Holdings Limited and Worley Limited. During her 30 year executive career, Anne has held a number of leadership positions in corporate and private banking with domestic and offshore banks including Westpac Banking Corporation, Australia and New Zealand Banking Group Ltd, and Bank of Singapore. Anne is the former Chairperson of Commonwealth Bank's financial advice companies and has served on the boards of The Citadel Group Ltd, Cuscal Ltd, HT&E Limited, Pioneer Credit Ltd, Notre Dame University, TAL Superannuation Fund, and HBF Limited (private and general insurance companies). Anne has experience in strategy, financial and nonfinancial risk, and corporate governance. Anne is also a Director of the Cyber Security Research Centre Ltd. She is also member of Risk & Technology Committee.
|Ms Sharon Lee Warburton||Non-Executive Director||Apr 2021|| |
Sharon has board and executive experience in corporate strategy, business operations, finance, accounting and risk management, along with expertise in governance and remuneration. She is currently a Non-Executive Director and Chair of the Audit and Risk Committee of Wesfarmers Limited, as well as being a Non-Executive Director of Gold Road Resources Limited and Worley Limited. Sharon has also been a part time member of the Takeovers Panel since 2015, and is an Adjunct Professor in Leadership and Strategy at Curtin University's Faculty of Business and Law. She is also member of Risk & Technology Committee.
|Mr David Ansell||Non-Executive Director||Oct 2013|| |
Mr Ansell has a career in consumer-facing organisations in Australia, Asia and the United States. David played a pivotal role in the start-up years of Foxtel, was CEO of advertising agency Saatchi & Saatchi, Managing Director of Mars Incorporated in Australia, and President of a global Mars unit based in the United States. David has a operating and supply chain skill set and understanding of brand and customer strategy. David recently stepped down as Managing Director of Jacobs Douwe Egberts Peets, after six years running Australia and New Zealand's largest pure play coffee Company. Since then, he has led the acquisition of the Campos Coffee Company, which he now Chairs as an Independent Director. David is a former Director of the peak body of cycling in this country, Cycling Australia, where he served for five years until early 2020. He is also member of Risk & Technology Committee.
|Ms Wendy Margaret Stops||Non-Executive Director||Apr 2021|| |
Ms Stops is Chair of the Risk & Technology Committee. She brings global information technology, operational and risk management experience with leadership roles in Asia Pacific and operational and risk management globally. Wendy is currently a Non-Executive Director with the Coles Group and Fitted for Work, a Council Member of the University of Melbourne, Chair of the Industry Advisory Board for the Melbourne Business School's Centre for Business Analytics, a member of the Digital Experts Advisory Panel for the Department of Prime Minister and Cabinet's Digital Taskforce and a member of the AICD's Governance of Technology & Innovation Panel. She was previously a Non-Executive Director of the Commonwealth Bank of Australia (2015-2020) and Altium Ltd (2018-2019).
|Mr Alastair Symington||Managing DirectorChief Executive Officer||Sep 2019|| |
Mr Symington brings global FMCG experience with leadership roles in health and beauty categories across multiple geographies. Prior to joining Blackmores Alastair was the Senior Vice President of APAC, Latin America and the Middle East for Coty based in Dubai. He has experience in commercial operations across multiple geographies during his time at P&G and Coty having held roles in Market Strategy and Planning across APAC (P&G) based in Singapore, Managing Director China Wella (P&G), based in Shanghai, Head of Emerging Markets Wella) P&G, based in Geneva, and SVP Consumer Beauty, Coty based in Dubai. Alastair started his career in Australia and has a deep understanding of consumer retail and brand marketing in the local market having held roles at both at Nestle and Gillette.
|Ms Erica Mann||Non-Executive Director||Sep 2021|| |
Ms Mann has experience and understanding of complementary medicines and naturopathic principles. She has experience in over-the-counter health care products. She has worked in leadership roles in organisations at the head of health technology developments. Erica's most recent executive role was President & Head of Bayer's Global Consumer Health Division, where she directed every aspect of consumer self-care companies globally. Erica also served as Chair of the World Self-Medication Industry, a body that sets standards and guidelines for the design and labelling of non-prescription medicines and dietary supplements. Erica currently serves as a Non-Executive Director of Kellogg Company (NYSE: K), Perrigo Company PLC (NYSE: PRGO) and Supervisory Board Member at Koninklijke DSM N.V (AMS: DSM). She previously held executive positions on the boards of South African Pharmaceutical Manufacturers' Association, Medicines Australia and the International Association of Infant Food Manufacturers.
|Mr Richard Conway||Company SecretaryGeneral Counsel||Jul 2021|| |
|Gunther Burghardt||Chief Financial Officer|| |
|Cecile Cooper||Chief Governance Officer|| |
|Joanne Smith||Chief Marketing and Innovation Officer|| |
|Jeremy Cowan||Chief Operations Officer|| |
|Jane Franks||Chief People Officer|| |
|Richard Conway||Company SecretaryGeneral Counsel|| |
|Adjunct Professor Lesley Braun||Director Blackmores Institute|| |
|Kitty Liu||Managing Director China|| |
|Dean Garvey||Managing Director International|| |
|HSBC Custody Nominees (Australia) Limited||3,611,759||18.65%|
|JP Morgan Nominees Australia Limited||2,986,113||15.42%|
|Mr M C Blackmore||2,197,467||11.35%|
|Citicorp Nominees Pty Limited||978,970||5.06%|
|National Nominees Limited||725,702||3.75%|
|Blackmore Foundation Pty Limited||696,535||3.60%|
|BNP Paribas Nominees Pty Ltd (DRP)||238,119||1.23%|
|BNP Paribas Nominees Pty Ltd (Agency Lending A/C)||225,981||1.17%|
|Mrs E M Whellan||150,347||0.78%|
|Mrs P G Wright||122,265||0.63%|
|Rathvale Pty Limited||113,088||0.58%|
|Marcus Blackmore Holdings P/L (Blackmores S/F A/C)||99,589||0.51%|
|Mr R Shepherd||88,179||0.46%|
|BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd DRP||56,219||0.29%|
|Netwealth Investments Limited (Wrap Services A/C)||41,974||0.22%|
|BNP Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C>||41,422||0.21%|
|Citicorp Nominees Pty Limited (Colonial First State Inv A/C)||40,071||0.21%|
|Powerwrap Limited (Scheme IML Trades A/C)||38,325||0.20%|
|Mr John Taylor||35,465||0.18%|
|Ms Margaret Dittman||32,191||0.17%|
Historically, Blackmores has paid dividends in March and September. In 2020, the Blackmores board decided not to pay its usual interim dividend, in light of the significant deterioration in the outlook for the second half due to COVID-19.
No further announcements have been made regarding Blackmores’ full year FY20 dividend payment.
Yes, historically Blackmores has offered a dividend reinvestment plan (DRP). When the DRP is active, shareholders can elect to reinvest all or part of their dividends in fully paid ordinary shares in Blackmores.